Sopharma AD (BUL:SFA)

Market Cap	1.92B +97.1%
Revenue (ttm)	2.69B +18.1%
Net Income	154.80M +78.0%
EPS	0.30 +68.7%
Shares Out	525.53M
PE Ratio	11.95
Forward PE	n/a
Dividend	0.06 (1.53%)
Ex-Dividend Date	Dec 18, 2025

Volume	17,765
Open	1.850
Previous Close	1.870
Day's Range	1.850 - 1.890
52-Week Range	1.092 - 2.000
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 1, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,932
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.